|
Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC. |
|
|
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer |
Consulting or Advisory Role - MedImmune |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Hutchison MediPharma; Roche; Simcere |
Speakers' Bureau - AstraZeneca; Hansoh; Roche |
Research Funding - AstraZeneca; Bristol-Myers Squibb; HenRui; Hutchison MediPharma; Roche |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb; Lilly |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Lilly |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Trans-Hit Biomarker |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Trans-Hit Biomarker |
Travel, Accommodations, Expenses - AstraZeneca |